---
reference_id: "PMID:34608458"
title: Unraveling the mechanisms of IVIG immunotherapy in MIS-C.
authors:
- Ganigara M
- Sharma C
- Bayry J
journal: Cell Rep Med
year: '2021'
doi: 10.1016/j.xcrm.2021.100431
content_type: abstract_only
---

# Unraveling the mechanisms of IVIG immunotherapy in MIS-C.
**Authors:** Ganigara M, Sharma C, Bayry J
**Journal:** Cell Rep Med (2021)
**DOI:** [10.1016/j.xcrm.2021.100431](https://doi.org/10.1016/j.xcrm.2021.100431)

## Content

1. Cell Rep Med. 2021 Oct 19;2(10):100431. doi: 10.1016/j.xcrm.2021.100431. Epub 
2021 Sep 30.

Unraveling the mechanisms of IVIG immunotherapy in MIS-C.

Ganigara M(1), Sharma C(2), Bayry J(3).

Author information:
(1)Division of Pediatric Cardiology, The University of Texas Southwestern 
Medical Center, Dallas, TX 75235, USA.
(2)Division of Pediatric Cardiology, Children's Hospital of San Antonio/Baylor 
College of Medicine, San Antonio, TX 78207, USA.
(3)Biological Sciences & Engineering, Indian Institute of Technology Palakkad, 
Palakkad 678 623, Kerala, India.

Comment on
    J Clin Invest. 2021 Oct 15;131(20):e147076. doi: 10.1172/JCI147076.

In The Journal of Clinical Investigation, Zhu et al.1 report that intravenous 
immunoglobulin (IVIG) targets IL-1β+ neutrophils to exert anti-inflammatory 
effects in multisystem inflammatory syndrome in children (MIS-C), a 
post-infectious inflammatory condition associated with COVID-19.

© 2021 The Author(s).

DOI: 10.1016/j.xcrm.2021.100431
PMCID: PMC8481087
PMID: 34608458 [Indexed for MEDLINE]

Conflict of interest statement: J.B. (at Institut National de la Santé et de la 
Recherche Médicale, Centre de Recherche des Cordeliers, Paris, France) has 
received research grants from CSL Behring, France, for investigation on the 
mechanisms of action of IVIG.